GE Healthcare Introduces Serena Bright, Industry’s First Contrast-Enhanced Guided Biopsy Solution
October 20 2020 - 9:00AM
Business Wire
GE Healthcare today announced the availability of Serena Bright™
in the United States. Serena Bright™ is the industry’s first
contrast-enhanced guided biopsy solution and will help empower
clinicians and patients in their fight against breast cancer.
Receiving U.S. Food and Drug Administration 510(k) clearance in
June, this technology allows clinicians to conduct breast biopsy
exams with contrast guidance using the same mammography equipment,
in the same room and with the same staff as the screening or
diagnostic mammogram.
Typically, for lesions found with contrast-enhanced mammography
and not seen on ultrasound, clinicians will use other imaging
guidance, such as MRI, for biopsy procedures. Following an abnormal
mammogram, it can take several weeks to get an MRI biopsy.1 As the
backlog of cancer screenings caused by COVID-19 persists, delays in
diagnosis will likely lead to presentation at more advanced stages
and poorer clinical outcomes, with one study pointing to a
potential increase of 33,890 excessive cancer deaths in the U.S.
alone.2
Serena Bright may help decrease these delays, allowing follow-up
biopsy procedures to be done in a matter of days, rather than
waiting several weeks for MRI biopsy. When compared to MRI-biopsy
guided therapy, the potential benefits of Contrast Enhanced
Spectral Mammography (CESM) biopsy include shortened procedure time
and improved overall patient experience.3,4
“In the current COVID-19 environment and requirements for
shorter appointments to allow physical distancing, time has become
our most precious asset,” said Dr. Anat Kornecki, Breast Imaging
Lead, Breast Care Program, St. Joseph’s Health Care London and
Scientist with Lawson Health Research Institute in London, Ontario.
“This new mammography-guided biopsy technique is a gamechanger, and
patients tell us it’s a very tolerable experience. It provides a
familiar setting, familiar technology and a more comfortable option
compared to MRI biopsies, which are longer and conducted with
patients lying face down. Ultimately, this may help provide women
with answers quickly.”
Key to this technology’s application is GE Healthcare’s
SenoBright™ HD CESM, a diagnostic breast exam with iodine-based
contrast that provides high sensitivity for more accurate breast
cancer diagnosis.5 By highlighting areas of unusual blood flow to
localize lesions that need to be biopsied, CESM biopsy – Serena
Bright™ – provides excellent image quality to help improve clinical
confidence.
“Now more than ever, it is critical we put the comfort of
patients first and get them answers as fast as possible. We are
proud to bring Serena Bright to our customers during a time when
this type of innovation is needed most,” said Agnes Berzsenyi,
President and CEO of Women’s Health and X-Ray at GE Healthcare. “We
hope this technology can help improve breast cancer outcomes for
women during this time of uncertainty.”
Health systems worldwide are looking to implement the Serena
Bright technology in their fight against breast cancer, with
Jefferson Health in Philadelphia being the first health care system
in the United States to offer this technology in late 2020.
For more information, visit
www.gehealthcare.com/products/mammography/serena-bright.
About GE Healthcare:
GE Healthcare is the $16.7 billion healthcare business of GE
(NYSE: GE). As a leading global medical technology and digital
solutions innovator, GE Healthcare enables clinicians to make
faster, more informed decisions through intelligent devices, data
analytics, applications and services, supported by its Edison
intelligence platform. With over 100 years of healthcare industry
experience and around 50,000 employees globally, the company
operates at the center of an ecosystem working toward precision
health, digitizing healthcare, helping drive productivity and
improve outcomes for patients, providers, health systems and
researchers around the world.
Follow us on Facebook, LinkedIn, Twitter and Insights for the
latest news, or visit our website www.gehealthcare.com for more
information.
1 Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E.
Delays in Diagnosis and Treatment of Breast Cancer: A Safety-Net
Population Profile. Journal of the National Comprehensive Cancer
Network : JNCCN. 2018;16(12):1451-1457. 2 Lai A, Pasea L,
Banerjee A, et al . Estimating excess mortality in people with
cancer and multimorbidity in the COVID-19 emergency. medRxiv.
Preprint posted online June 1, 2020.
doi:10.13140/RG.2.2.34254.82242 3 Data on file 2020 GE Healthcare;
From first to last image. 4 Accessed on 10/16/2020:
https://www.cedars-sinai.edu/Patients/Programs-and-Services/Imaging-Center/For-Patients/Exams-by-Procedure/MRI/MR-Guided-Breast-Biopsy/MR-Guided-Breast-Needle-Core-Biopsy-Procedure-Information.aspx
5 Daniauxet al. Arch Gynecol Obstet , 2015
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201020005163/en/
Kate Rodgers Katlynn.rodgers@ge.com +1 (262) 202-5430
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Aug 2024 to Sep 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Sep 2023 to Sep 2024